AlgalPure (Schizochytrium sp.)

AlgalPure is a DHA-rich algal oil derived from Schizochytrium sp. microalgae containing 32-50% docosahexaenoic acid. DHA supports brain function, eye health, and cardiovascular wellness through membrane incorporation and anti-inflammatory eicosanoid production.

Origin & History

AlgalPure is a branded DHA-rich algal oil derived from the microalgae Schizochytrium sp., a spherical unicellular microorganism (10-20 μm) that produces high levels of omega-3 fatty acids. It is produced through fermentation of strains like RT100 or LU 310, followed by cell recovery, hexane extraction, and multiple refining steps including degumming, neutralization, bleaching, winterization, and deodorization.

Historical & Cultural Context

No historical or traditional medicinal use is documented for AlgalPure. Schizochytrium sp. is a modern fermented microalgae source developed for commercial omega-3 production without ties to traditional medicine systems.

Health Benefits

• No human clinical trials available - evidence quality: absent
• Animal study in fish showed comparable growth performance to fish oil supplementation - evidence quality: preliminary animal data only
• Contains DHA at 32-50% concentration, a known essential omega-3 fatty acid - evidence quality: compositional data only
• Low contaminant profile with heavy metals below 0.1 ppm - evidence quality: analytical testing data
• GRAS status achieved for Schizochytrium sp. LU 310 oil - evidence quality: regulatory approval

How It Works

DHA from AlgalPure incorporates into cell membrane phospholipids, particularly in brain and retinal tissues, enhancing membrane fluidity and neuronal signaling. DHA serves as a precursor for specialized pro-resolving mediators like resolvins and protectins, which help resolve inflammation. The omega-3 fatty acid also influences gene expression through peroxisome proliferator-activated receptors (PPARs) and reduces pro-inflammatory cytokine production.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for AlgalPure were found in the research dossier. The only study mentioned was an animal trial in rohu fish that compared Schizochytrium sp. powder to fish oil in feed formulations, showing comparable growth performance.

Clinical Summary

Currently, no human clinical trials have been conducted specifically on AlgalPure, representing absent evidence quality for human health outcomes. One animal study in fish demonstrated that AlgalPure supplementation produced comparable growth performance to traditional fish oil supplementation. The DHA content of 32-50% provides the primary therapeutic potential, as DHA itself has extensive clinical research supporting cognitive and cardiovascular benefits. However, specific efficacy data for this particular algal extract remains limited to preliminary animal research.

Nutritional Profile

AlgalPure (Schizochytrium sp.) is a microalgae-derived oil concentrate with the following compositional profile: Primary bioactive is DHA (docosahexaenoic acid) at 32–50% of total fatty acids by weight, with typical commercial preparations standardized to approximately 35–40% DHA. Total fat content constitutes the majority of dry weight (>50%), as this is an oil-rich thraustochytrid microalgae. DPA (docosapentaenoic acid, n-6) is a co-occurring fatty acid at approximately 10–15% of total fatty acids, which is characteristic of Schizochytrium sp. and distinguishes it from fish oil sources. EPA (eicosapentaenoic acid) content is negligible (<1%). Saturated fatty acids, particularly palmitic acid (C16:0), are present at approximately 25–35% of total fatty acids. Protein content in the whole algae biomass is modest (~10–15% dry weight) but largely absent in the refined oil form. Carbohydrates and fiber are minimal in oil extract form. Micronutrients include naturally occurring astaxanthin and other carotenoids (minor amounts in whole biomass). Heavy metal contaminants (mercury, lead, cadmium, arsenic) are below 0.1 ppm, reflecting the controlled fermentation production environment rather than ocean harvesting. Bioavailability of DHA from algal oil is considered equivalent to fish oil based on pharmacokinetic comparisons in animal models; the triglyceride or ethyl ester form affects absorption rate, with triglyceride forms generally showing superior bioavailability (~25% greater absorption vs. ethyl esters).

Preparation & Dosage

No clinically studied human dosage ranges are available. Product specifications indicate DHA content of ≥400 mg/g (32-50%) in oil form and 100-130 mg/g (10%) in powder form. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other omega-3 sources, vitamin E, astaxanthin, phospholipids, vitamin D

Safety & Interactions

AlgalPure appears generally well-tolerated based on its DHA content profile, though comprehensive safety studies are lacking. High-dose omega-3 supplementation may increase bleeding risk when combined with anticoagulant medications like warfarin or aspirin. Individuals with seafood allergies should note that algal sources typically pose lower allergenic risk compared to fish-derived omega-3s. Pregnant and breastfeeding women should consult healthcare providers before supplementation, despite DHA being essential for fetal brain development.